Business Context and Reporting Period
Akebia Therapeutics, Inc. (AKBA) filed this Form 8-K on September 4, 2020, to disclose the entry into a material definitive agreement. The Company, a biopharmaceutical firm, operates through its wholly owned subsidiary, Keryx Biopharmaceuticals, Inc.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The primary financial disclosure relates to a specific contractual obligation:
- Total Contractual Obligation: Approximately $81.4 million through the end of the term.
- Obligation Nature: Reimbursement of facility construction costs and purchase of minimum quantities of Auryxia (ferric citrate) drug substance.
- Term: September 4, 2020, to December 31, 2026, with automatic one-year renewals unless terminated.
Material Changes Versus Prior Period
The Company amended and restated its Product Manufacture and Supply and Facility Construction Agreement with BioVectra Inc., originally entered into in 2017 and amended in 2018. Key changes include:
- Reduced Minimum Quantities: The new agreement lowers the minimum quantities of Auryxia drug substance Keryx is obligated to purchase compared to the Original Agreement.
- Lower Total Cost: The total cost of approximately $81.4 million is substantially lower than the contractual obligation under the Original Agreement.
- Strategic Intent: The amendment aligns with the Company's plan to lower the cost of goods sold for Auryxia.
Outlook, Risks, and Management Commentary
Management indicated that the agreement supports cost-reduction strategies for the Company's lead product, Auryxia. The agreement includes customary terms regarding indemnification, intellectual property, confidentiality, and quality requirements. Risks associated with the agreement include the potential for early termination by either party upon the occurrence of certain conditions and the possibility that the total cost may decrease further if specific conditions are met.
Investor Verification Checklist
- Verify the specific conditions under which the $81.4 million obligation may decrease.
- Review the full text of the Amended and Restated Agreement (Exhibit 10.1) for detailed termination clauses and quality requirements.
- Assess the impact of reduced minimum purchase quantities on future revenue projections for Auryxia.
- Confirm the status of the New Facility construction and its readiness for supply.